Current drug development portfolio for antimalarial therapies
Current drug development portfolio for antimalarial therapies
复制标题
DOI：
10.1016/j.coph.2005.05.004
复制
发表时间：
2005-10-01
影响因子：
4
通讯作者：
Ward, SA
中科院分区：
文献类型：
--
作者：
Biagini, GA;O'Neill, PM;Ward, SA
In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.
